AEterna Zentaris Competitors and Similar CompaniesClear all

AEterna Zentaris's competitors and similar companies include Organon R&D Finland, Agile Therapeutics, HRA Pharma and ProFem.

	AEterna Zentaris AEterna Zentaris is a drug development company specialized in oncology and endocrine therapy. The Companys product pipeline	Organon R&D Finland Organon R&D Finland (formerly Forendo Pharma) is a drug development company focusing on novel treatments in women's health.	Agile Therapeutics Agile Therapeutics is the pharmaceutical company developing contraceptive healthcare products for women.	HRA Pharma HRA Pharma is a consumer healthcare company.	ProFem ProFem is a pharmaceutical company with a focus on the clinical development of drugs for the treatment of gynecological diseases.
Founding Date	Founding Date N/A	Founding Date 2013	Founding Date 1997	Founding Date 1996	Founding Date 2012
Type	Type Public	Type Subsidiary	Type Public	Type Private	Type Private
Tags	Tags Healthcare clinics drug development pharma women's health	Tags Healthcare drug development pharma women's health	Tags Healthcare drug development pharma women's health	Tags Healthcare drug development pharma women's health	Tags Healthcare drug development pharma women's health
Locations	Locations Summerville, US HQ Toronto, CA Frankfurt Am Main, DE	Locations Åbo, FI HQ	Locations Princeton, US HQ Brentwood, US	Locations Châtillon, FR HQ Machelen, BE Wiesbaden, DE Roma, IT Lisboa, PT Madrid, ES Nyon, CH see more	Locations Wien, AT HQ Herentals, BE
Employees	Employees 1168% decrease	Employees 1930% decrease	Employees 1515% increase	Employees 139	Employees 4
Valuation ($)	Valuation ($) 17.5 m	Valuation ($) N/A	Valuation ($) 10.4 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $7.5m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $19.6m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods $4.9m (FY, 2025)	Cost of goods N/A	Cost of goods $9m (FY, 2023)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit $2.6m (FY, 2025)	Gross profit N/A	Gross profit $10.6m (FY, 2023)	Gross profit N/A	Gross profit N/A
Net income	Net income ($10.4m) (FY, 2025)	Net income N/A	Net income ($14.5m) (FY, 2023)	Net income N/A	Net income N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 30.7m	Total funding raised $ 85m	Total funding raised N/A	Total funding raised N/A